Name | Number of supported studies | Average coverage | |
---|---|---|---|
macrophage | 29 studies | 33% ± 14% | |
astrocyte | 16 studies | 37% ± 19% | |
monocyte | 14 studies | 29% ± 7% | |
dendritic cell | 13 studies | 28% ± 7% | |
classical monocyte | 12 studies | 30% ± 9% | |
microglial cell | 12 studies | 40% ± 13% | |
non-classical monocyte | 11 studies | 24% ± 7% | |
conventional dendritic cell | 10 studies | 23% ± 5% | |
endothelial cell | 9 studies | 29% ± 12% | |
myeloid cell | 9 studies | 37% ± 11% | |
adipocyte | 9 studies | 62% ± 10% | |
type I pneumocyte | 8 studies | 24% ± 8% | |
fibroblast | 8 studies | 29% ± 15% | |
oligodendrocyte | 7 studies | 27% ± 9% | |
T cell | 6 studies | 25% ± 12% | |
neutrophil | 6 studies | 25% ± 12% | |
mononuclear phagocyte | 5 studies | 27% ± 11% | |
mucosal invariant T cell | 5 studies | 25% ± 5% | |
plasmacytoid dendritic cell | 5 studies | 35% ± 7% | |
CD4-positive, alpha-beta T cell | 5 studies | 19% ± 3% | |
pericyte | 5 studies | 21% ± 5% | |
glutamatergic neuron | 5 studies | 42% ± 21% | |
GABAergic neuron | 4 studies | 33% ± 13% | |
epithelial cell | 4 studies | 26% ± 15% | |
retinal pigment epithelial cell | 4 studies | 27% ± 7% | |
endothelial cell of lymphatic vessel | 4 studies | 23% ± 11% | |
leukocyte | 4 studies | 25% ± 8% | |
renal principal cell | 4 studies | 35% ± 9% | |
abnormal cell | 3 studies | 19% ± 2% | |
kidney loop of Henle epithelial cell | 3 studies | 18% ± 3% | |
tissue-resident macrophage | 3 studies | 35% ± 12% | |
ciliated cell | 3 studies | 32% ± 6% | |
lymphocyte | 3 studies | 28% ± 14% | |
retinal cone cell | 3 studies | 35% ± 11% | |
CD8-positive, alpha-beta memory T cell | 3 studies | 21% ± 4% | |
gamma-delta T cell | 3 studies | 20% ± 1% | |
innate lymphoid cell | 3 studies | 20% ± 4% | |
regulatory T cell | 3 studies | 16% ± 0% | |
ependymal cell | 3 studies | 39% ± 10% | |
group 3 innate lymphoid cell | 3 studies | 27% ± 2% | |
muscle cell | 3 studies | 23% ± 10% | |
interneuron | 3 studies | 40% ± 16% | |
oligodendrocyte precursor cell | 3 studies | 33% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 100% | 13327.11 | 576 / 578 | 97% | 70.85 | 1117 / 1155 |
brain | 94% | 8230.28 | 2489 / 2642 | 100% | 140.31 | 704 / 705 |
breast | 97% | 30485.36 | 444 / 459 | 94% | 76.19 | 1055 / 1118 |
skin | 86% | 7669.49 | 1559 / 1809 | 96% | 59.17 | 455 / 472 |
kidney | 90% | 13462.75 | 80 / 89 | 88% | 94.68 | 795 / 901 |
esophagus | 77% | 5470.85 | 1119 / 1445 | 97% | 52.78 | 178 / 183 |
ovary | 86% | 4123.45 | 155 / 180 | 79% | 32.63 | 341 / 430 |
intestine | 62% | 3211.15 | 595 / 966 | 94% | 37.54 | 493 / 527 |
bladder | 67% | 4486.48 | 14 / 21 | 83% | 40.26 | 417 / 504 |
stomach | 55% | 3185.52 | 198 / 359 | 94% | 36.61 | 268 / 286 |
uterus | 55% | 2298.34 | 93 / 170 | 87% | 50.81 | 400 / 459 |
prostate | 68% | 3485.73 | 166 / 245 | 63% | 16.32 | 317 / 502 |
pancreas | 17% | 777.44 | 56 / 328 | 96% | 70.02 | 170 / 178 |
tonsil | 0% | 0 | 0 / 0 | 100% | 60.04 | 45 / 45 |
adipose | 100% | 41381.25 | 1203 / 1204 | 0% | 0 | 0 / 0 |
spleen | 99% | 9905.64 | 238 / 241 | 0% | 0 | 0 / 0 |
adrenal gland | 53% | 2838.66 | 136 / 258 | 45% | 17.54 | 104 / 230 |
muscle | 98% | 68416.87 | 785 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 98% | 51.40 | 78 / 80 |
peripheral blood | 95% | 21919.17 | 886 / 929 | 0% | 0 | 0 / 0 |
blood vessel | 86% | 11298.72 | 1147 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 83% | 61.53 | 24 / 29 |
thymus | 23% | 1062.72 | 151 / 653 | 50% | 14.18 | 300 / 605 |
liver | 34% | 2629.47 | 76 / 226 | 33% | 25.37 | 133 / 406 |
heart | 27% | 1381.38 | 230 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006000 | Biological process | fructose metabolic process |
GO_0046835 | Biological process | carbohydrate phosphorylation |
GO_0006003 | Biological process | fructose 2,6-bisphosphate metabolic process |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0004331 | Molecular function | fructose-2,6-bisphosphate 2-phosphatase activity |
GO_0005515 | Molecular function | protein binding |
GO_0005524 | Molecular function | ATP binding |
GO_0003873 | Molecular function | 6-phosphofructo-2-kinase activity |
Gene name | PFKFB3 |
Protein name | 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase (EC 2.7.1.105) (6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3) 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase (EC 2.7.1.105) (6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3) 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (6PF-2-K/Fru-2,6-P2ase 3) (PFK/FBPase 3) (6PF-2-K/Fru-2,6-P2ase brain/placenta-type isozyme) (Renal carcinoma antigen NY-REN-56) (iPFK-2) [Includes: 6-phosphofructo-2-kinase (EC 2.7.1.105); Fructose-2,6-bisphosphatase (EC 3.1.3.46)] 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase (EC 2.7.1.105) |
Synonyms | |
Description | FUNCTION: Catalyzes both the synthesis and degradation of fructose 2,6-bisphosphate. . |
Accessions | ENST00000379775.9 [Q16875-1] Q5VX20 ENST00000639949.1 H0Y483 ENST00000360521.7 [Q16875-2] F2Z2I2 A0A1W2PNV9 Q9BQU1 ENST00000414237.5 ENST00000379789.8 [Q16875-3] ENST00000490474.5 ENST00000450232.1 H0YDV0 ENST00000379785.5 ENST00000475881.5 A0A1W2PR17 ENST00000625260.2 Q9BQU2 Q16875 ENST00000640683.1 ENST00000536985.6 [Q16875-4] Q9BQU3 ENST00000626882.2 Q5W015 ENST00000317350.8 ENST00000467491.5 ENST00000477914.5 ENST00000441697.1 Q9H178 ENST00000461744.5 |